Update on therapy for melanoma: opportunities for patient selection and overcoming tumor resistance
- 10 January 2007
- journal article
- review article
- Published by Informa UK Limited in Expert Review of Anticancer Therapy
- Vol. 7 (1), 79-88
- https://doi.org/10.1586/14737140.7.1.79
Abstract
The incidence of malignant melanoma is rising faster than any other malignancy. Although earlier stage patients can be cured with surgical resection with or without adjuvant therapy, a significant number of patients go on to develop disseminated disease. Currently, limited therapeutic options exist for patients with metastatic melanoma. Recent studies suggest that patient selection is feasible and may enable the restriction of treatment to those most likely to benefit. Additionally, several potential mechanisms of tumor resistance have been identified creating opportunities for circumventing them. This article will review current strategies for patient selection and overcoming therapeutic resistance. These strategies hold the promise of extending the clinical benefits of current therapies as well as facilitating the development of additional and more active treatments.Keywords
This publication has 86 references indexed in Scilit:
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Interferons, interferon‐like cytokines, and their receptorsImmunological Reviews, 2004
- Phase II Study of Paclitaxel and Carboplatin for Malignant MelanomaAmerican Journal of Clinical Oncology, 2002
- Prognostic Factors in Metastatic Melanoma: A Pooled Analysis of Eastern Cooperative Oncology Group TrialsJournal of Clinical Oncology, 2000
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Regression in skin tumours: A common phenomenonAustralasian Journal of Dermatology, 1997
- A phase II study of taxol in patients with malignant melanomaInvestigational New Drugs, 1991
- A phase II trial of taxol in metastatic melanomaCancer, 1990
- Phase-II Study of Recombinant α2-Interferon in Advanced Malignant MelanomaJournal of Interferon Research, 1986
- Dimethyl triazeno imidazole carboxamide and combination therapy for melanoma IV. Late results after complete response to chemotherapy (central oncology group protocols 7130, 7131, and 7131A)Cancer, 1984